A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC).

被引：0
|
作者：
Karzai, Fatima H.
Madan, Ravi Amrit
Apolo, Andrea Borghese
Parnes, Howard L.
Wright, John Joseph
Trepel, Jane B.
Beatson, Melony A.
Harold, Nancy
Couvillon, Anna
Steinberg, Seth M.
Price, Douglas K.
Gulley, James L.
Figg, William Douglas
Dahut, William L.
机构：
[1] NCI, Med Oncol Branch, Bethesda, MD 20892 USA
[2] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[3] NCI, Bethesda, MD 20892 USA
[4] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
[5] NCI, Rockville, MD USA
[6] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5095
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
    R Petrioli
    A Pascucci
    R Conca
    G Chiriacò
    E Francini
    G Bargagli
    A I Fiaschi
    A Manganelli
    G De Rubertis
    G Barbanti
    R Ponchietti
    G Francini
    British Journal of Cancer, 2011, 104 : 613 - 619
  • [32] Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
    Petrioli, R.
    Pascucci, A.
    Conca, R.
    Chiriaco, G.
    Francini, E.
    Bargagli, G.
    Fiaschi, A. I.
    Manganelli, A.
    De Rubertis, G.
    Barbanti, G.
    Ponchietti, R.
    Francini, G.
    BRITISH JOURNAL OF CANCER, 2011, 104 (04) : 613 - 619
  • [33] The dynamics of biomarkers and bone imaging associated with oral cabozantinib therapy in metastatic castrate resistant prostate cancer (mCRPC)
    Vaishampayan, Ulka N.
    Podgorski, Izabela
    Lawhorn-Crews, Jawana
    Heilbrun, Lance K.
    Heath, Elisabeth I.
    Dobson, Kimberlee
    Smith, Daryn W.
    Shields, Anthony Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Small, Eric Jay
    Lance, Raymond S.
    Redfern, Charles H.
    Millard, Frederick E.
    Gardner, Thomas A.
    Karsh, Lawrence Ivan
    Dawson, Nancy Ann
    McCoy, Candice
    Stubbs, Andrew
    DeVries, Todd
    dela Rosa, Corazon P.
    Sheikh, Nadeem A.
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment
    Gernone, A.
    Pagliarulo, A.
    Calderoni, G.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [36] Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Adesunloye, Bamidele
    Huang, Xuan
    Ning, Yangmin M.
    Madan, Ravi A.
    Gulley, James L.
    Beatson, Melony
    Kluetz, Paul Gustav
    Adelberg, David
    Arlen, Philip M.
    Parnes, Howard L.
    Mulquin, Marcia
    Steinberg, Seth M.
    Wright, John Joseph
    Trepel, Jane B.
    Dawson, Nancy Ann
    Chen, Clara
    Apolo, Andrea Borghese
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [37] Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC)
    Cetnar, J. P.
    Rosen, M. A.
    Vaughn, D. J.
    Haas, N. B.
    Troxel, A. B.
    Song, H.
    Adluru, G.
    Flaherty, K. T.
    O'Dwyer, P. J.
    Amaravadi, R. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Phase II trial of intravenous carboplatin (C), oral everolimus (E), and prednisone (P) in docetaxel-pretreated (DP) metastatic castrate-resistant prostate cancer (mCRPC): A Prostate Cancer Clinical Trials Consortium study.
    Veeraputhiran, Muthu Kumaran
    Shevrin, Daniel H.
    Stein, Mark N.
    Heilbrun, Lance K.
    Smith, Daryn
    Li, Jing
    Dickow, Brenda
    Heath, Elisabeth I.
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Overall survival (OS) prognostic factors in metastatic castrate-resistant prostate cancer (mCRPC) patients retreated with docetaxel (D)
    Shah, Shilpa Rashmikant
    Albany, Costantine
    Hahn, Noah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] A phase II trial of cabozantinib (Cabo) in patients (pts) with castrate-resistant prostate cancer (CRPC) metastatic to bone (NCT01428219).
    Grivas, Petros
    Daignault, Stephanie
    Cooney, Kathleen A.
    Jacobson, Jon
    Yablon, Corrie
    Ross, Brian Dale
    Chenevert, Thomas L.
    Galban, Craig J.
    Rehemtulla, Alnawaz
    Keller, Evan T.
    Kunju, Priya
    Mehra, Rohit
    Escara-Wilke, June
    Shelley, Greg
    Pienta, Kenneth James
    Hussain, Maha
    Smith, David C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345